Trial Details

Not Recruiting
Basic Information
Clinical ID c5085
Identifier EUCTR2016-004677-40-SE
Trial Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

Yes
Conditions Ulcerative Colitis MedDRA version: 20.0.Level: PT.Classification code 10009900.Term: Colitis ulcerative.System Organ Class: 10017947 - Gastrointestinal disorders.;Therapeutic area: Diseases [C] - Digestive Syste
Interventions Product Name: RisankizumabProduct Code: ABBV-066Pharmaceutical Form: Solution for infusionINN or Proposed INN: RISANKIZUMABCurrent Sponsor code: ABBV-066Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equal
Participant Information
Sponsor AbbVie Deutschland GmbH & Co. KG
City NULL
Country/Region Russia;United States;Czech Republic;Egypt;Malaysia;Portugal;Greece;Sweden;Austria;Latvia;Netherlands;China;Brazil;South Korea;Poland;Slovakia;Slovenia;Chile;France;Lithuania;Bulgaria;Serbia;Croatia;Colombia;Argentina;Romania;Japan;Ukraine;United Kingdom;S
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement NULL
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE2|PHASE3
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL